15th Nov 2024 10:02
RTW Biotech Opportunities Ltd - investment fund managed by RTW Investments LP that specialises in the life sciences sector - Notes Shanghai-based portfolio company Corxel Pharmaceuticals Co Ltd, formerly Ji Xing Pharmaceuticals Ltd, has had its new drug application for Aficamten accepted by China's National Medical Products Administration. Aficamten is a drug treatment for obstructive hypertrophic cardiomyopathy, a genetic heart condition diagnosed in around 130,000 to 330,000 patients in China, in which the heart muscle becomes abnormally thick and limits the heart's pumping function. The drug has also received breakthrough therapy designation from the US Food & Drug Administration. Corxel was founded and launched by RTW Investments in 2019.
Current stock price: USD1.55, up 0.5% in London on Friday morning
12-month change: up 37%
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved